Literature DB >> 8919742

Immunity to reinfection and immunization of male guinea pigs against urethral infection with the agent of guinea pig inclusion conjunctivitis.

T L Patterson1, R G Rank.   

Abstract

BACKGROUND AND OBJECTIVES: There is little information available on immunity of males to chlamydial infection after recovering from a primary urethral infection or after immunization with chlamydial antigen. The guinea pig model of genital infection using the chlamydial agent of guinea pig inclusion conjunctivitis was utilized to evaluate the protective immune response in these circumstances. GOAL: To determine whether immunity to reinfection develops after a primary urethral infection and whether immunity develops as a result of immunization with inactivated chlamydiae. STUDY
DESIGN: Groups of five male guinea pigs each in two separate experiments were infected in the urethra with chlamydiae and challenged with a fresh inoculum at either 30, 75, or 150 days after infection. The course of the challenge infection was then determined. Similarly, guinea pigs were immunized subcutaneously with ultraviolet-inactivated chlamydial elementary bodies and the course of urethral infection was determined when inoculated 2 weeks after immunization.
RESULTS: Male guinea pigs were highly resistant to reinfection after a primary urethral infection. Animals that were immunized with inactivated chlamydiae generally became infected upon challenge, but the intensity of the infection was markedly reduced.
CONCLUSIONS: Male guinea pigs possess protective mechanisms that make them more resistant to repeat chlamydial genital infection for a longer period of time than is seen in female guinea pigs. In addition, immunization of males with inactivated chlamydial antigen by a parenteral route is able to elicit a protective response to urethral infection with chlamydiae.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8919742     DOI: 10.1097/00007435-199603000-00010

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  7 in total

1.  A new murine model for testing vaccines against genital Chlamydia trachomatis infections in males.

Authors:  Sukumar Pal; Annahita K Sarcon; Luis M de la Maza
Journal:  Vaccine       Date:  2010-10-13       Impact factor: 3.641

2.  Local host response to chlamydial urethral infection in male guinea pigs.

Authors:  Yin Wang; Uma Nagarajan; Leah Hennings; Anne K Bowlin; Roger G Rank
Journal:  Infect Immun       Date:  2010-02-01       Impact factor: 3.441

3.  Characterization of chlamydial genital infection resulting from sexual transmission from male to female guinea pigs and determination of infectious dose.

Authors:  Roger G Rank; Anne K Bowlin; Ronald L Reed; Toni Darville
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

Review 4.  The guinea pig as a model of infectious diseases.

Authors:  Danielle J Padilla-Carlin; David N McMurray; Anthony J Hickey
Journal:  Comp Med       Date:  2008-08       Impact factor: 0.982

5.  New murine model for the study of Chlamydia trachomatis genitourinary tract infections in males.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

6.  Plasmid-cured Chlamydia caviae activates TLR2-dependent signaling and retains virulence in the guinea pig model of genital tract infection.

Authors:  Lauren C Frazer; Toni Darville; Kumar Chandra-Kuntal; Charles W Andrews; Matthew Zurenski; Margaret Mintus; Yasser M AbdelRahman; Robert J Belland; Robin R Ingalls; Catherine M O'Connell
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

7.  Use of a Guinea pig-specific transcriptome array for evaluation of protective immunity against genital chlamydial infection following intranasal vaccination in Guinea pigs.

Authors:  Shradha Wali; Rishein Gupta; Ronald L Veselenak; Yansong Li; Jieh-Juen Yu; Ashlesh K Murthy; Andrew P Cap; M Neal Guentzel; James P Chambers; Guangming Zhong; Roger G Rank; Richard B Pyles; Bernard P Arulanandam
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.